Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor-Reference-Cited by-同舟云学术

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

Published:2006-04 Issue:4 Volume:5 Page:995-1006
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Albert Daniel H.,Tapang Paul,Magoc Terrance J.,Pease Lori J.,Reuter David R.,Wei Ru-Qi,Li Junling,Guo Jun,Bousquet Peter F.,Ghoreishi-Haack Nayereh S.,Wang Baole,Bukofzer Gail T.,Wang Yi-Chun,Stavropoulos Jason A.,Hartandi Kresna,Niquette Amanda L.,Soni Nirupama,Johnson Eric F.,McCall J. Owen,Bouska Jennifer J.,Luo Yanping,Donawho Cherrie K.,Dai Yujia,Marcotte Patrick A.,Glaser Keith B.,Michaelides Michael R.,Davidsen Steven K.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives;Discover Oncology;2024-07-03

2. RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development;European Journal of Medicinal Chemistry;2024-02

3. DeepWalk-aware graph attention networks with CNN for circRNA–drug sensitivity association identification;Briefings in Functional Genomics;2023-12-07

4. Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,4-oxadiazole incorporated indazole-isoxazole derivatives;Synthetic Communications;2023-11-17

5. The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia;Mini-Reviews in Medicinal Chemistry;2023-10-06